Showing results (11-20 of 100) with videos related to
Sort By:
Pageof 10
The Journal of Clinical Psychiatry|August 25, 2004
Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychoticsJean-Pierre Lindenmayer, Els Eerdekens, Sally A Berry, et al.The Journal of Clinical Psychiatry|November 26, 2008
Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical reviewCarlos Saavedra-Velez, Anna Yusim, Deepti Anbarasan, et al.Journal of Clinical Psychopharmacology|July 9, 2020
Persistent Barriers to the Use of Long-Acting Injectable Antipsychotics for the Treatment of SchizophreniaJean-Pierre Lindenmayer, Ira D Glick, Hiteshkumar Talreja, et al.Psychopharmacology Bulletin|September 10, 2008
The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled studyJean-Pierre Lindenmayer, David Brown, Sherry Liu, et al.Schizophrenia Research|April 27, 2013
A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunitiesJean-Pierre Lindenmayer, Henry Nasrallah, Michael Pucci, et al.Journal of Clinical Psychopharmacology|February 25, 2011
A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorderJean-Pierre Lindenmayer, Leslie Citrome, Anzalee Khan, et al.The Journal of Clinical Psychiatry|March 29, 2007
A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophreniaJean-Pierre Lindenmayer, Anzalee Khan, Adel Iskander, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 20, 2006
Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorderJean-Pierre Lindenmayer, Akbar Khan, Mariëlle Eerdekens, et al.BMC Psychiatry|November 17, 2007
Item response analysis of the Positive and Negative Syndrome ScaleDarcy A Santor, Haya Ascher-Svanum, Jean-Pierre Lindenmayer, et al.Schizophrenia Research|October 19, 2020
The psychometric properties of the Self-Evaluation of Negative Symptoms Scale (SNS) in treatment-resistant schizophrenia (TRS)Abraham Goldring, Sophia Borne, Amanda Hefner, et al.Pageof 10